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To the Editor: In their elegant review, Bakris et al.1 explored the
role of selective inhibitors of sodium glucose co-trans-
porter 2 (SGLT2) (SLC5A2, a sodium–glucose transporter in
the renal proximal tubule) in diabetes mellitus type 2 (DM2).
Indeed, early studies indicate that dapagliflozin is able to reduce
HbA1C levels in DM2.2 However, based on our experience
regarding a patient with a SLC5A2 mutation, and cases of similar
patients from the literature,3 we feel some caution is warranted.
Our patient is a 33-year-old Turkish man with no past medical
history, and no medication or parental consanguinity. He has
hypotension (90/60 mm Hg) and persistently high serum
sodium and bicarbonate levels (150 and 33 mmol/l, respectively).
As massive amounts of glucose are filtered daily, perturbed
glucose reabsorption causes profound glucosuria, osmotic
diuresis, and subsequent urinary sodium loss. Indeed,
patients with SLC5A2 mutations are often severely volume
depleted, as evidenced by orthostatic complaints and a
fivefold increase in their plasma renin values.3 A high
angiotensin II level stimulates the sodium–hydrogen exchan-
ger type 3 in the proximal tubule to reabsorb sodium at the
expense of alkalosis. Thus, these patients depend on their
renin–angiotensin system to stay upright. As many diabetic
patients are treated with inhibitors of the renin–angiotensin
system, SGLT2 inhibitors may induce unwanted effects,
such as hypotension and reduced glomerular filtration, when
used in combination with these drugs. However, if one
looks at the bright side, the natriuretic effect of the SGLT2
inhibitors may improve the typical volume expansion in
DM2. Moreover, reducing proximal sodium reabsorption
may even reduce glomerular hyperfiltration.4 Time alone can
tell which of these effects will prevail.
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We read with interest the letter by Zietse and Hoorn1
regarding their patient and the caution with the use of
sodium glucose co-transporter 2 (SGLT2) agents in such a
setting. We are aware of the fact that these agents have the
potential to cause volume depletion if not properly
monitored. However, in the more typical clinical setting,
it would be unusual to have a patient develop volume
depletion simply from this agent. Similar to agents that
block the renin–angiotensin system, it is appreciated that
changes in volume status can adversely affect kidney
function and may occur with any agent, including diuretics
as well as the aforementioned classes in any patient.
Given that the increased urine output per day generated
by this class of agents is in the range of 400–600 ml, it
would be uncommon to predict volume depletion simply
on this basis. Moreover, this increase in urine volume does
not necessarily continue indefinitely, or else one would get
severely dehydrated eventually. There are compensatory
mechanisms for this volume loss, thirst being a prominent
one. The lack of thirst or a disrupted thirst mechanism
may have been a problem in the patient described. Lastly,
clinical trials completed to date have not turned up
patients with problems such as that described. Thus,
clinicians, as always, are required to be vigilant about
concomitant medications and diseases that might affect the
volume status of patients. The SGLT2 agents will be a
welcome adjunct to the armamentarium of agents that help
manage the worldwide epidemic of diabetes.
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